{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:21:12Z","timestamp":1783131672311,"version":"3.54.6"},"reference-count":65,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014761","name":"Natural Science Foundation of Qingdao","doi-asserted-by":"publisher","award":["25-1-1-242-zyyd-jch"],"award-info":[{"award-number":["25-1-1-242-zyyd-jch"]}],"id":[{"id":"10.13039\/501100014761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011324","name":"Qingdao University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019446","name":"Medical and Health Science and Technology Development Project of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019446","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2025MS1362"],"award-info":[{"award-number":["ZR2025MS1362"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bbadis.2026.168281","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:37:32Z","timestamp":1777617452000},"page":"168281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted inhibition of the H3K27ac\/OGT\/O-GlcNAcylation axis to overcome gemcitabine-induced chemotherapy resistance in bladder cancer"],"prefix":"10.1016","volume":"1872","author":[{"given":"Zhijuan","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdi","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"74","key":"10.1016\/j.bbadis.2026.168281_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"74","key":"10.1016\/j.bbadis.2026.168281_bb0010","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"324","key":"10.1016\/j.bbadis.2026.168281_bb0015","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.bbadis.2026.168281_bb0020","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.euf.2019.10.016","article-title":"Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer","volume":"6","author":"Motterle","year":"2020","journal-title":"Eur. Urol. Focus"},{"issue":"33","key":"10.1016\/j.bbadis.2026.168281_bb0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.clon.2021.03.020","article-title":"Adjuvant and Neoadjuvant Radiation Therapy for Locally Advanced Bladder Cancer","volume":"33","author":"Baumann","year":"2021","journal-title":"Clin. Oncol. (R Coll Radiol)"},{"issue":"29","key":"10.1016\/j.bbadis.2026.168281_bb0030","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1097\/MJT.0000000000000934","article-title":"Immunotherapy in Bladder Cancer","volume":"29","author":"Konala","year":"2022","journal-title":"Am. J. Ther."},{"issue":"7","key":"10.1016\/j.bbadis.2026.168281_bb0035","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fonc.2017.00260","article-title":"Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity","volume":"7","author":"Prasanna","year":"2017","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168281_bb0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14796694.1.1.7","article-title":"Role of gemcitabine in cancer therapy","volume":"1","author":"Toschi","year":"2005","journal-title":"Future Oncol."},{"key":"10.1016\/j.bbadis.2026.168281_bb0045","doi-asserted-by":"crossref","unstructured":"Zhu H, Wang Y, Wei T, Zhao X, Li F, Li Y et al., KAT8\/MOF-mediated anti-cancer mechanism of gemcitabine in human bladder cancer cells, Biomol Ther (Seoul). 29 (29) (2021) 184\u2013194. doi:https:\/\/doi.org\/10.4062\/biomolther.2020.111.","DOI":"10.4062\/biomolther.2020.111"},{"issue":"31","key":"10.1016\/j.bbadis.2026.168281_bb0050","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ymthe.2022.11.004","article-title":"Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer","volume":"31","author":"Shi","year":"2023","journal-title":"Mol. Ther."},{"issue":"62","key":"10.1016\/j.bbadis.2026.168281_bb0055","article-title":"RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer","volume":"62","author":"Ono","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbadis.2026.168281_bb0060","doi-asserted-by":"crossref","unstructured":"Lee H W, Kang M J, Kwon Y J, Abdi Nansa S, Jung E H, Kim S H et al., Targeted Inhibition of O-Linked beta-N-Acetylglucosamine Transferase as a Promising Therapeutic Strategy to Restore Chemosensitivity and Attenuate Aggressive Tumor Traits in Chemoresistant Urothelial Carcinoma of the Bladder, Biomedicines 10 (10) (2022) doi:https:\/\/doi.org\/10.3390\/biomedicines10051162.","DOI":"10.3390\/biomedicines10051162"},{"issue":"10","key":"10.1016\/j.bbadis.2026.168281_bb0065","doi-asserted-by":"crossref","first-page":"7178","DOI":"10.7150\/thno.43093","article-title":"Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer","volume":"10","author":"Wang","year":"2020","journal-title":"Theranostics"},{"issue":"500","key":"10.1016\/j.bbadis.2026.168281_bb0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.canlet.2020.12.006","article-title":"Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11(p110)","volume":"500","author":"Chen","year":"2021","journal-title":"Cancer Lett."},{"issue":"164","key":"10.1016\/j.bbadis.2026.168281_bb0075","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1053\/j.gastro.2023.02.025","article-title":"Targeting UBE2T potentiates Gemcitabine efficacy in pancreatic cancer by regulating Pyrimidine metabolism and replication stress","volume":"164","author":"Jiang","year":"2023","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.bbadis.2026.168281_bb0080","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s12079-023-00766-7","article-title":"Tripartite motif-containing 9 promoted proliferation and migration of bladder cancer cells through CEACAM6-Smad2\/3 axis","volume":"17","author":"Zhang","year":"2023","journal-title":"J. Cell Commun. Signal."},{"key":"10.1016\/j.bbadis.2026.168281_bb0085","doi-asserted-by":"crossref","unstructured":"Du Y, Yang Z, Shi H, Chen Z, Chen R, Zhou F et al., E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA, Cell Death Dis. 15 (15) (2024) 340. doi:https:\/\/doi.org\/10.1038\/s41419-024-06729-z.","DOI":"10.1038\/s41419-024-06729-z"},{"issue":"8","key":"10.1016\/j.bbadis.2026.168281_bb0090","article-title":"Histone Modifications and Cancer","volume":"8","author":"Audia","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"29","key":"10.1016\/j.bbadis.2026.168281_bb0095","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2174\/0929867328666211108105214","article-title":"Histone Modifications and their Role in Epigenetics of Cancer","volume":"29","author":"Zaib","year":"2022","journal-title":"Curr. Med. Chem."},{"issue":"372","key":"10.1016\/j.bbadis.2026.168281_bb0100","article-title":"The tale of a tail: histone H4 acetylation and the repair of DNA breaks","volume":"372","author":"Dhar","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"issue":"277","key":"10.1016\/j.bbadis.2026.168281_bb0105","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci."},{"issue":"63","key":"10.1016\/j.bbadis.2026.168281_bb0110","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"issue":"87","key":"10.1016\/j.bbadis.2026.168281_bb0115","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: Emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"18","key":"10.1016\/j.bbadis.2026.168281_bb0120","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"261","key":"10.1016\/j.bbadis.2026.168281_bb0125","article-title":"Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma","volume":"261","author":"Liu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168281_bb0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13148-016-0225-2","article-title":"Histone acetyltransferases: challenges in targeting bi-substrate enzymes","volume":"8","author":"Wapenaar","year":"2016","journal-title":"Clin. Epigenetics"},{"issue":"562","key":"10.1016\/j.bbadis.2026.168281_bb0135","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41586-018-0621-1","article-title":"Transcription factor dimerization activates the p300 acetyltransferase","volume":"562","author":"Ortega","year":"2018","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bbadis.2026.168281_bb0140","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.7150\/thno.73223","article-title":"Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"issue":"75","key":"10.1016\/j.bbadis.2026.168281_bb0145","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00018-017-2717-4","article-title":"CREBBP and p300 lysine acetyl transferases in the DNA damage response","volume":"75","author":"Dutto","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"7","key":"10.1016\/j.bbadis.2026.168281_bb0150","doi-asserted-by":"crossref","first-page":"51301","DOI":"10.18632\/oncotarget.10117","article-title":"P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer","volume":"7","author":"Ono","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2026.168281_bb0155","doi-asserted-by":"crossref","unstructured":"Ono H, Kato T, Murase Y, Nakamura Y, Ishikawa Y, Watanabe S et al., C646 inhibits G2\/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer, Sci. Rep. 11 (11) (2021) 10078. doi:https:\/\/doi.org\/10.1038\/s41598-021-89530-8.","DOI":"10.1038\/s41598-021-89530-8"},{"key":"10.1016\/j.bbadis.2026.168281_bb0160","doi-asserted-by":"crossref","unstructured":"Wang Y M, Gu M L, Meng F S, Jiao W R, Zhou X X, Yao H P et al., Histone acetyltransferase p300\/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines, Int. J. Oncol. 51 (51) (2017) 1860\u20131868. doi:https:\/\/doi.org\/10.3892\/ijo.2017.4176.","DOI":"10.3892\/ijo.2017.4176"},{"key":"10.1016\/j.bbadis.2026.168281_bb0165","doi-asserted-by":"crossref","unstructured":"Bowers E M, Yan G, Mukherjee C, Orry A, Wang L, Holbert M A et al., Virtual ligand screening of the p300\/CBP histone acetyltransferase: identification of a selective small molecule inhibitor, Chem. Biol. 17 (17) (2010) 471\u2013482. doi:https:\/\/doi.org\/10.1016\/j.chembiol.2010.03.006.","DOI":"10.1016\/j.chembiol.2010.03.006"},{"key":"10.1016\/j.bbadis.2026.168281_bb0170","doi-asserted-by":"crossref","unstructured":"Nishimura Y, Sasagawa S, Ariyoshi M, Ichikawa S, Shimada Y, Kawaguchi K et al., Systems pharmacology of adiposity reveals inhibition of EP300 as a common therapeutic mechanism of caloric restriction and resveratrol for obesity, Front. Pharmacol. 6 (6) (2015) 199. doi:https:\/\/doi.org\/10.3389\/fphar.2015.00199.","DOI":"10.3389\/fphar.2015.00199"},{"key":"10.1016\/j.bbadis.2026.168281_bb0175","doi-asserted-by":"crossref","unstructured":"Wen L, Xie B, Li H, Huang J, Shi Y, Tao Y et al., EP300 through upregulating the expression of vimentin to promote the progression of chordoma, Neurosurg. Focus 56 (56) (2024) E17. doi:https:\/\/doi.org\/10.3171\/2024.2.FOCUS244.","DOI":"10.3171\/2024.2.FOCUS244"},{"key":"10.1016\/j.bbadis.2026.168281_bb0180","doi-asserted-by":"crossref","unstructured":"Yan G, Eller M S, Elm C, Larocca C A, Ryu B, Panova I P et al., Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells, J. Invest. Dermatol. 133 (133) (2013) 2444\u20132452. doi:https:\/\/doi.org\/10.1038\/jid.2013.187.","DOI":"10.1038\/jid.2013.187"},{"key":"10.1016\/j.bbadis.2026.168281_bb0185","doi-asserted-by":"crossref","unstructured":"Zhang M, Kan D, Zhang B, Chen X, Wang C, Chen S et al., P300\/SP1 complex mediating elevated METTL1 regulates CDK14 mRNA stability via internal m7G modification in CRPC, J. Exp. Clin. Cancer Res. 42 (42) (2023) 215. doi:https:\/\/doi.org\/10.1186\/s13046-023-02777-z.","DOI":"10.1186\/s13046-023-02777-z"},{"key":"10.1016\/j.bbadis.2026.168281_bb0190","doi-asserted-by":"crossref","unstructured":"Liu Y C, Lin Y H, Chi H C, Huang P S, Liao C J, Liou Y S et al., CRNDE acts as an epigenetic modulator of the p300\/YY1 complex to promote HCC progression and therapeutic resistance, Clin. Epigenetics 14 (14) (2022) 106. doi:https:\/\/doi.org\/10.1186\/s13148-022-01326-3.","DOI":"10.1186\/s13148-022-01326-3"},{"key":"10.1016\/j.bbadis.2026.168281_bb0195","doi-asserted-by":"crossref","unstructured":"Zhou F, Yang X, Zhao H, Liu Y, Feng Y, An R et al., Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer, Theranostics 8 (8) (2018) 5200\u20135212. doi:https:\/\/doi.org\/10.7150\/thno.27806.","DOI":"10.7150\/thno.27806"},{"issue":"14","key":"10.1016\/j.bbadis.2026.168281_bb0200","article-title":"Protein O-GlcNAcylation in multiple immune cells and its therapeutic potential","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Immunol."},{"issue":"566","key":"10.1016\/j.bbadis.2026.168281_bb0205","article-title":"O-GlcNAcylation in cancer development and immunotherapy","volume":"566","author":"He","year":"2023","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.bbadis.2026.168281_bb0210","article-title":"Targeting O-GlcNAcylation to overcome resistance to anti-cancer therapies","volume":"12","author":"Very","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbadis.2026.168281_bb0215","doi-asserted-by":"crossref","unstructured":"Wang L, Chen S, Zhang Z, Zhang J, Mao S, Zheng J et al., Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer, BMC Cancer 18 (18) (2018) 1141. doi:https:\/\/doi.org\/10.1186\/s12885-018-5033-y.","DOI":"10.1186\/s12885-018-5033-y"},{"issue":"7","key":"10.1016\/j.bbadis.2026.168281_bb0220","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41420-021-00715-6","article-title":"Oncogenic microRNA-181d binding to OGT contributes to resistance of ovarian cancer cells to cisplatin","volume":"7","author":"Huang","year":"2021","journal-title":"Cell Death Discov."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168281_bb0225","article-title":"Stepwise molecular mechanisms responsible for chemoresistance in bladder cancer cells","volume":"8","author":"Mun","year":"2022","journal-title":"Cell Death Discov."},{"issue":"13","key":"10.1016\/j.bbadis.2026.168281_bb0230","article-title":"Nkx2.8 promotes chemosensitivity in bladder urothelial carcinoma via transcriptional repression of MDR1","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"issue":"19","key":"10.1016\/j.bbadis.2026.168281_bb0235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12964-020-00627-5","article-title":"Drug resistance and Cancer stem cells","volume":"19","author":"Li","year":"2021","journal-title":"Cell Commun. Signal"},{"issue":"28","key":"10.1016\/j.bbadis.2026.168281_bb0240","article-title":"Recent advances in bladder cancer stem cells (BCSCs): a descriptive review of emerging therapeutic targets","volume":"28","author":"Li","year":"2025","journal-title":"iScience"},{"issue":"115","key":"10.1016\/j.bbadis.2026.168281_bb0245","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/cr500452k","article-title":"Protein lysine acetylation by p300\/CBP","volume":"115","author":"Dancy","year":"2015","journal-title":"Chem. Rev."},{"issue":"70","key":"10.1016\/j.bbadis.2026.168281_bb0250","article-title":"p300-mediated lysine 2-hydroxyisobutyrylation regulates glycolysis","volume":"70","author":"Huang","year":"2018","journal-title":"Mol. Cell"},{"issue":"13","key":"10.1016\/j.bbadis.2026.168281_bb0255","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/1541-7786.MCR-15-0034","article-title":"PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer","volume":"13","author":"Ono","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbadis.2026.168281_bb0260","doi-asserted-by":"crossref","unstructured":"Song P, Lv D, Yang L, Zhou J, Yan X, Liu Z et al., Di-(2-ethylhexyl) phthalate promotes benign prostatic hyperplasia through KIF11-Wnt\/beta-catenin signaling pathway, Ecotoxicol. Environ. Saf. 281 (281) (2024) 116602. doi:https:\/\/doi.org\/10.1016\/j.ecoenv.2024.116602.","DOI":"10.1016\/j.ecoenv.2024.116602"},{"key":"10.1016\/j.bbadis.2026.168281_bb0265","article-title":"Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics","author":"Jiang","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbadis.2026.168281_bb0270","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008976","article-title":"Gemcitabine for unresectable, locally advanced or metastatic bladder cancer","author":"Shelley","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"41","key":"10.1016\/j.bbadis.2026.168281_bb0275","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ctrv.2015.03.004","article-title":"Molecular biology and targeted therapies for urothelial carcinoma","volume":"41","author":"Seront","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"1866","key":"10.1016\/j.bbadis.2026.168281_bb0280","article-title":"Protein post-translational modifications: a key factor in colorectal cancer resistance mechanisms","volume":"1866","author":"Bi","year":"2023","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"issue":"160","key":"10.1016\/j.bbadis.2026.168281_bb0285","article-title":"Investigation of cancer drug resistance mechanisms by phosphoproteomics","volume":"160","author":"Boulos","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbadis.2026.168281_bb0290","doi-asserted-by":"crossref","unstructured":"Baietti M F, Sewduth R N, Novel therapeutic approaches targeting post-translational modifications in lung cancer, Pharmaceutics 15 (15) (2023) doi:https:\/\/doi.org\/10.3390\/pharmaceutics15010206.","DOI":"10.3390\/pharmaceutics15010206"},{"issue":"6","key":"10.1016\/j.bbadis.2026.168281_bb0295","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"6","author":"Han","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"16","key":"10.1016\/j.bbadis.2026.168281_bb0300","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/14737140.2016.1143777","article-title":"The safety and efficacy of gemcitabine for the treatment of bladder cancer","volume":"16","author":"Schlack","year":"2016","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"14","key":"10.1016\/j.bbadis.2026.168281_bb0305","article-title":"The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168281_bb0310","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.tranon.2015.04.002","article-title":"Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics","volume":"8","author":"Vallo","year":"2015","journal-title":"Transl. Oncol."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168281_bb0315","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbadis.2026.168281_bb0320","doi-asserted-by":"crossref","unstructured":"Kikuchi M, Morita S, Wakamori M, Sato S, Uchikubo-Kamo T, Suzuki T et al., Epigenetic mechanisms to propagate histone acetylation by p300\/CBP, Nat. Commun. 14 (14) (2023) 4103. doi:https:\/\/doi.org\/10.1038\/s41467-023-39735-4.","DOI":"10.1038\/s41467-023-39735-4"},{"key":"10.1016\/j.bbadis.2026.168281_bb0325","doi-asserted-by":"crossref","unstructured":"Natu A, Verma T, Khade B, Thorat R, Gera P, Dhara S et al., Histone acetylation: a key determinant of acquired cisplatin resistance in cancer, Clin. Epigenetics 16 (16) (2024) 8. doi:https:\/\/doi.org\/10.1186\/s13148-023-01615-5.","DOI":"10.1186\/s13148-023-01615-5"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926001444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926001444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:52:48Z","timestamp":1783129968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443926001444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0925443926001444"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168281","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted inhibition of the H3K27ac\/OGT\/O-GlcNAcylation axis to overcome gemcitabine-induced chemotherapy resistance in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"168281"}}